Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group

被引：2

作者：

Motomura, Kazuya ^{[1
]}

Sasaki, Keita ^{[2
]}

Sugii, Narushi ^{[3
]}

Yamaguchi, Shigeru ^{[4
]}

Inoue, Hirotaka ^{[5
]}

Oshima, Akito ^{[6
]}

Tanaka, Kazuhiro ^{[7
]}

Otani, Yoshihiro ^{[8
]}

Shirahata, Mitsuaki ^{[9
]}

Shibahara, Ichiyo ^{[10
]}

Nagane, Motoo ^{[11
]}

Tsuzuki, Shunsuke ^{[12
]}

Matsutani, Tomoo ^{[13
]}

Tsukamoto, Yoshihiro ^{[14
]}

Kijima, Noriyuki ^{[15
]}

Asano, Kenichiro ^{[16
]}

Ohno, Makoto ^{[17
]}

Inoue, Akihiro ^{[18
]}

Mineharu, Yohei ^{[19
]}

Miyake, Keisuke ^{[20
]}

Mitobe, Yuta ^{[21
]}

Hanihara, Mitsuto ^{[22
]}

Kawanishi, Yu ^{[23
]}

Deguchi, Shoichi ^{[24
]}

Saito, Masato ^{[25
]}

Matsuda, Ryosuke ^{[26
]}

Ujifuku, Kenta ^{[27
]}

Arita, Hideyuki ^{[28
]}

Sato, Yuichi ^{[29
]}

Yamashita, Shinji ^{[30
]}

Yonezawa, Ushio ^{[31
]}

Yamaguchi, Junya ^{[1
]}

Momii, Yasutomo ^{[32
]}

Ogawa, Takahiro ^{[33
]}

Kambe, Atsushi ^{[34
]}

Ohba, Shigeo ^{[35
]}

Fukai, Junya ^{[36
]}

Saito, Norihiko ^{[37
]}

Kinoshita, Masashi ^{[38
]}

Sumi, Koichiro ^{[39
]}

Otani, Ryohei ^{[40
]}

Uzuka, Takeo ^{[41
]}

Takebe, Noriyoshi ^{[42
]}

Koizumi, Shinichiro ^{[43
]}

Saito, Ryuta ^{[1
]}

Arakawa, Yoshiki ^{[19
]}

Narita, Yoshitaka ^{[17
]}

机构：

[1] Nagoya Univ, Grad Sch Med, Dept Neurosurg, 65 Tsurumai Co,Showa Ku, Nagoya, Japan

[2] JCOG Data Ctr, Natl Canc Ctr Hosp, Operat Off, 5-1-1 Tsukiji,Chuo Ku, Tokyo, Japan

[3] Univ Tsukuba Hosp, Dept Neurosurg, 2-1-1 Amakubo, Tsukuba, Japan

[4] Hokkaido Univ, Fac Med, Dept Neurosurg, North 15,West 7,Kita Ku, Sapporo, Japan

[5] Kumamoto Univ, Grad Sch Med Sci, Dept Neurosurg, 1-1-1,Honjo,Chuo Ku, Kumamoto, Japan

[6] Yokohama City Univ, Dept Neurosurg, 3-9 Fukuura, Kanazawa, Yokohama, Japan

[7] Kobe Univ Hosp, Dept Neurosurg, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe, Japan

[8] Okayama Univ, Fac Med Dent & Pharmaceut Sci, Dept Neurol Surg, 2-5-1 Shikata Cho,Kita Ku, Okayama, Japan

[9] Med Univ Int Med Ctr, Dept Neurosurg Neurooncol, 1397-1 Yamane,Hidaka, Saitama, Saitama, Japan

[10] Kitasato Univ, Dept Neurosurg, Sch Med, 1-15-1,Minami Ku,Sagamihara, Kitasato, Japan

[11] Kyorin Univ, Fac Med, Dept Neurosurg, 6-20-2 Shinkawa, Tokyo, Japan

[12] Tokyo Womens Med Univ, Dept Neurosurg, 8-1 Kawada-Cho,Shinjuku Ku, Tokyo, Japan

[13] Chiba Univ, Grad Sch Med, Dept Neurol Surg, 1-8-1 Inohana,Chuou Ku, Chiba, Japan

[14] Niigata Univ, Brain Res Inst, Dept Neurosurg, 1-757 Asahimachi Dori,Chuo Ku, Niigata, Japan

[15] Osaka Univ, Grad Sch Med, Dept Neurosurg, 2-2 Yamadaoka,Suita, Osaka, Japan

[16] Hirosaki Univ, Grad Sch Med, Dept Neurosurg, Zaifu Cho 5, Hirosaki, Japan

[17] Natl Canc Ctr, Dept Neurosurg & Neurooncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo, Japan

[18] Ehime Uunivers, Sch Med, Dept Neurosurg, 454 Shitsukawa, Toon, Ehime, Japan

[19] Kyoto Univ, Grad Sch Med, Dept Neurosurg, 54 Kawahara Cho,Shogoin Sakyo Ku, Kyoto, Japan

[20] Kagawa Univ, Fac Med, Dept Neurol Surg, 1750-1 Ikenobe,Miki Cho, Kagawa, Japan

[21] Yamagata Univ Hosp, Dept Neurosurg, 2-2-2 Iida-Nishi, Yamagata, Japan

[22] Univ Yamanashi, Dept Neurosurg, 1110 Shimokato, Kofu, Yamanashi, Japan

[23] Kochi Univ, Kochi Med Sch, Dept Neurosurg, Oko Cho,Nanko Ku, Kohasu, Kochi, Japan

[24] Shizuoka Canc Ctr, Dept Neurosurg, Shimonagakubo 1007, Nagaizumi, Shizuoka, Japan

[25] Asahikawa Med Univ, Dept Neurosurg, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Japan

[26] Nara Med Univ, Dept Neurosurg, Shijo Cho 840, Kashihara, Nara, Japan

[27] Nagasaki Univ, Grad Sch Biomed Sci, Dept Neurosurg, 1-7-1 Sakamoto, Nagasaki, Japan

[28] Osaka Int Canc Inst, Dept Neurosurg, 3-1-69, Otemae, Chuo Ku, Osaka, Japan

[29] Iwate Med Univ, Sch Med, Dept Neurosurg, 2-1-1 Idai Dori, Shiwa, Iwate, Japan

[30] Miyazaki Univ, Dept Neurosurg, 5200 Kihara Kiyotake, Miyazaki, Japan

[31] Hiroshima Univ Hosp, Dept Neurosurg, 1-2-3 Minami Ku, Kasumi, Hiroshima, Japan

[32] Oita Univ, Fac Med, Dept Neurosurg, 1-1 Idaigaoka Hasama Machi, Yufu, Oita, Japan

[33] Kyoto Prefectural Univ Med, Dept Neurosurg, 465 Kajii Cho,Kawaramachi-Hirokoji,Kamigyo Ku, Kyoto, Japan

[34] Tottori Univ, Fac Med, Dept Brain & Neurosci, Div Neurosurg, 36-1 Nishi Cho, Yonago, Tottori, Japan

[35] Fujita Hlth Univ, Dept Neurosurg, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi, Japan

[36] Wakayama Med Univ, Sch Med, Dept Neurol Surg, 811-1 Kimiidera, Wakayama, Japan

[37] Toho Univ, Ohashi Med Ctr, Dept Neurosurg, 2-22-36 Ohashi, Meguro, Tokyo, Japan

[38] Kanazawa Univ, Dept Neurosurg, 13-1 Takara Machi, Kanazawa, Japan

[39] Nihon Univ, Sch Med, Dept Neurol Surg, 30-1 Oyaguchikamicho,Itabashi Ku, Tokyo, Japan

[40] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Neurosurg, 3-18-22 Honkomagome,Bunkyo Ku, Tokyo, Japan

[41] Dokkyo Med Univ Hosp, Dept Neurosurg, 880 Kitakobayashi,Mibu Machi, Tochigi, Japan

[42] Med Res Inst Kitano Hosp, Dept Neurosurg, PIIF Tazuke Kofukai, 2-4-20 Ohgimachi,Kita-Ku, Osaka, Japan

[43] Hamamatsu Univ Sch Med, Dept Neurosurg, 1-20-1 Handayama,Higashi Ku, Hamamatsu, Shizuoka, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 54卷 / 10期

关键词：

glioblastoma; primary central nervous system lymphoma; treatment regimen; high-cost medical care; cost; HIGH-DOSE METHOTREXATE; RANDOMIZED PHASE-III; CHEMOTHERAPY; TEMOZOLOMIDE; GLIOBLASTOMA; RADIOTHERAPY; TRIAL; BEVACIZUMAB; CONCOMITANT; RITUXIMAB;

D O I：

10.1093/jjco/hyae116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan and the costs involved.Methods We conducted a questionnaire survey regarding treatment selections for newly diagnosed GBM and PCNSL treated between July 2021 and June 2022 among 47 institutions in the Japan Clinical Oncology Group-Brain Tumor Study Group. We calculated the total cost and cost per month of the initial therapy for newly diagnosed GBM or PCNSL.Results The most used regimen (46.8%) for GBM in patients aged <= 74 years was 'Surgery + radiotherapy concomitant with temozolomide'. This regimen's total cost was 7.50 million JPY (Japanese yen). Adding carmustine wafer implantation (used in 15.0%), TTFields (used in 14.1%), and bevacizumab (BEV) (used in 14.5%) to the standard treatment of GBM increased the cost by 1.24 million JPY for initial treatment, and 1.44 and 0.22 million JPY per month, respectively. Regarding PCNSL, 'Surgery (biopsy) + rituximab, methotrexate, procarbazine, and vincristine (R-MPV) therapy' was the most used regimen (42.5%) for patients of all ages. This regimen incurred 1.07 million JPY per month. The three PCNSL regimens based on R-MPV therapy were in ultra-high-cost medical care (exceeding 1 million JPY per month).Conclusions Treatment of malignant brain tumors is generally expensive, and cost-ineffective treatments such as BEV are frequently used. We believe that the results of this study can be used to design future economic health studies examining the cost-effectiveness of malignant brain tumors. As regimens used in GBM or PCNSL are costly, we believe that it will be necessary in the future to take cost-effectiveness into consideration in selecting a treatment.

引用

页码：1123 / 1131

页数：9

共 50 条

[41] Parental heat exposure and risk of childhood brain tumor: A Children's oncology Group Study
Bunin, Greta R.
Robison, Leslie L.
Blegel, Jaclyn A.
Pollack, Ian F.
Rorke-Adams, Lucy B.
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 164 (03) : 222 - 231
[42] EUROPEAN NEURO-ONCOLOGY QUALITY ASSURANCE (ENOQUA): AN EORTC BRAIN TUMOR GROUP STUDY
Razis, Evangelia
Hau, Peter
Gorlia, Thierry
Andratschke, Nicolaus
Baumert, Brigitta
Lohmann, Philipp
Vernadou, Anastasia
Gempt, Jens
De Vos, Filip
NEURO-ONCOLOGY, 2024, 26
[43] EMOTIONAL DYNAMIC SUPPORT GROUP FOR PARENTS OF CHILDREN WITH A MALIGNANT BRAIN TUMOR
Dayan-Sharabi, Michal
Ben-Gal, Yael
Toledano, Helen
PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1023 - 1023
[44] An overview of the medical-physics-related verification system for radiotherapy multicenter clinical trials by the Medical Physics Working Group in the Japan Clinical Oncology Group-Radiation Therapy Study Group
Nishio, Teiji
Nakamura, Mitsuhiro
Okamoto, Hiroyuki
Kito, Satoshi
Minemura, Toshiyuki
Ozawa, Shuichi
Kumazaki, Yu
Ishikawa, Masayori
Tohyama, Naoki
Kurooka, Masahiko
Nakashima, Takeo
Shimizu, Hidetoshi
Suzuki, Ryusuke
Ishikura, Satoshi
Nishimura, Yasumasa
JOURNAL OF RADIATION RESEARCH, 2020, 61 (06) : 999 - 1008
[45] A case-control study of childhood brain tumors and fathers' hobbies: a Children's Oncology Group study
Rosso, Andrea L.
Hovinga, Mary E.
Rorke-Adams, Lucy B.
Spector, Logan G.
Bunin, Greta R.
CANCER CAUSES & CONTROL, 2008, 19 (10) : 1201 - 1207
[46] POSTOPERATIVE CHEMOTHERAPY AND DELAYED RADIOTHERAPY IN INFANTS WITH BRAIN-TUMORS - A PEDIATRIC ONCOLOGY GROUP-STUDY
DUFFNER, P
HOROWITZ, M
KRISCHER, J
KUN, L
COHEN, M
FRIEDMAN, H
SANFORD, A
BURGER, P
FREEMAN, C
JAMES, H
ANNALS OF NEUROLOGY, 1991, 30 (03) : 484 - 484
[47] Phase I/II Study of Radiofrequency Ablation for Malignant Renal Tumors: Japan Interventional Radiology in Oncology Study Group 0701
Mimura, Hidefumi
Arai, Yasuaki
Yamakado, Koichiro
Sone, Miyuki
Takeuchi, Yoshito
Miki, Tsuneharu
Gobara, Hideo
Sakuhara, Yusuke
Yamamoto, Takanobu
Sato, Yozo
Kanazawa, Susumu
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2016, 39 (05) : 717 - 723
[48] Phase I/II Study of Radiofrequency Ablation for Malignant Renal Tumors: Japan Interventional Radiology in Oncology Study Group 0701
Hidefumi Mimura
Yasuaki Arai
Koichiro Yamakado
Miyuki Sone
Yoshito Takeuchi
Tsuneharu Miki
Hideo Gobara
Yusuke Sakuhara
Takanobu Yamamoto
Yozo Sato
Susumu Kanazawa
CardioVascular and Interventional Radiology, 2016, 39 : 717 - 723
[49] THE EXPERIENCE OF MEDICAL CARE-RELATED DECISIONS AMONG MALIGNANT BRAIN TUMOR PATIENTS IN JAPAN: QUALITATIVE INTERVIEWS
Numata, Hanako
Noguchi-Watanabe, Maiko
Tanaka, Shota
Takayanagi, Shunsaku
Mukasa, Akitake
Saito, Nobuhito
Yamamoto-Mitani, Noriko
NEURO-ONCOLOGY, 2017, 19 : 211 - 211
[50] Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors - A study by the Italian Trials In Medical Oncology Group
DiBartolomeo, M
Bajetta, E
Buzzoni, R
Mariani, L
Carnaghi, C
Somma, L
Zilembo, N
DiLeo, A
CANCER, 1996, 77 (02) : 402 - 408

← 1 2 3 4 5 →